Logo Medical XPRT
Companies
Products
Services
Software
Training
Applications
Sign in
List your business

Advertising options
  1. Home
  2. News
  3. manganese
Show results for
Products
Services
Applications

Companies

News
Articles
Downloads

Refine by
Date

  • Older

Manganese Articles & Analysis

15 news found

Custom MOF Development Services for Precise Antibody Drug Delivery   

Custom MOF Development Services for Precise Antibody Drug Delivery  

Customization Services for Enhanced Delivery CD Formulation’s expertise covers a range of MOF types, including those based on zinc, copper, iron, manganese, and aluminum. Each type has distinct properties: · Zinc-based MOFs: Known for stability and a large surface area. ...

ByCD Formulation


Galera to Present at Jefferies Healthcare Conference

Galera to Present at Jefferies Healthcare Conference

Galera’s selective dismutase mimetic product candidate avasopasem manganese (GC4419, also referred to as avasopasem) is being evaluated for radiotherapy-induced toxicities. The Company’s second product candidate, rucosopasem manganese (GC4711, also referred to as rucosopasem), is in clinical-stage development to augment the anti-cancer efficacy of ...

ByGalera Therapeutics, Inc.


Galera Announces Oral Presentation at 2022 American Society of Clinical Oncology (ASCO) Annual Meeting Detailing Results from Phase 3 ROMAN Trial of Avasopasem

Galera Announces Oral Presentation at 2022 American Society of Clinical Oncology (ASCO) Annual Meeting Detailing Results from Phase 3 ROMAN Trial of Avasopasem

There is currently no drug approved to prevent or treat SOM for these patients. About Avasopasem Avasopasem manganese (avasopasem, or GC4419) is a selective small molecule dismutase mimetic in development for the reduction of radiation-induced severe oral mucositis (SOM) in patients with locally advanced head and neck cancer (HNC) and for the reduction of radiation-induced ...

ByGalera Therapeutics, Inc.


Galera Announces Plan to Submit Avasopasem NDA by Year End

Galera Announces Plan to Submit Avasopasem NDA by Year End

(Nasdaq: GRTX), a clinical-stage biopharmaceutical company focused on developing and commercializing a pipeline of novel, proprietary therapeutics that have the potential to transform radiotherapy in cancer, today announced its intent to file a New Drug Application (NDA) for avasopasem manganese (avasopasem) for the treatment of radiotherapy-induced severe oral mucositis (SOM) in ...

ByGalera Therapeutics, Inc.


Galera Announces Topline Results from Phase 2a AESOP Trial of Avasopasem for Chemoradiotherapy-Induced Esophagitis

Galera Announces Topline Results from Phase 2a AESOP Trial of Avasopasem for Chemoradiotherapy-Induced Esophagitis

No Grade 4 or 5 esophagitis in patients treated with avasopasem Galera Therapeutics, Inc. (Nasdaq: GRTX), a clinical-stage biopharmaceutical company focused on developing and commercializing a pipeline of novel, proprietary therapeutics that have the potential to transform radiotherapy in cancer, today announced topline results from the six-week, Phase 2a, open-label, single-arm AESOP trial of ...

ByGalera Therapeutics, Inc.


Galera to Present at 2022 American Society of Clinical Oncology (ASCO) Annual Meeting

Galera to Present at 2022 American Society of Clinical Oncology (ASCO) Annual Meeting

Oral Presentation Title: ROMAN: Phase 3 trial of avasopasem manganese (GC4419) for severe oral mucositis (SOM) in patients receiving chemoradiotherapy (CRT) for locally advanced, nonmetastatic head and neck cancer (LAHNC) Abstract Number: 6005 Presenter: Carryn M. ...

ByGalera Therapeutics, Inc.


New independent market research says 84% US healthcare professionals likely to use Orviglance imaging agent in target population

New independent market research says 84% US healthcare professionals likely to use Orviglance imaging agent in target population

” Orviglance is a novel manganese-based oral contrast agent for MR imaging developed to improve the detection and visualization of focal liver lesions (including liver metastases and primary tumors) in patients with severely reduced kidney function. ...

ByAscelia Pharma AB


Ascelia Pharma successfully completes Orviglance Hepatic Impairment Study

Ascelia Pharma successfully completes Orviglance Hepatic Impairment Study

About Orviglance (previously referred to as Mangoral) Orviglance (manganese chloride tetrahydrate) is a novel oral contrast agent for MR-imaging developed to improve the detection and visualization of focal liver lesions (including liver metastases and primary tumors) in patients with reduced kidney function. ...

ByAscelia Pharma AB


Galera to Present at H.C. Wainwright BioConnect Conference

Galera to Present at H.C. Wainwright BioConnect Conference

Galera’s selective dismutase mimetic product candidate avasopasem manganese (GC4419, also referred to as avasopasem) is being evaluated for radiotherapy-induced toxicities. The Company’s second product candidate, rucosopasem manganese (GC4711, also referred to as rucosopasem), is in clinical-stage development to augment the anti-cancer efficacy of ...

ByGalera Therapeutics, Inc.


Galera Announces Primary Endpoint Met Statistical Significance in Corrected Topline Efficacy Data of Phase 3 ROMAN Trial of Avasopasem

Galera Announces Primary Endpoint Met Statistical Significance in Corrected Topline Efficacy Data of Phase 3 ROMAN Trial of Avasopasem

Galera’s selective dismutase mimetic product candidate avasopasem manganese (GC4419, also referred to as avasopasem) is being evaluated for radiotherapy-induced toxicities. The Company’s second product candidate, rucosopasem manganese (GC4711, also referred to as rucosopasem), is in clinical-stage development to augment the anti-cancer efficacy of ...

ByGalera Therapeutics, Inc.


EPA Issues ICR Concerning Health Effects Research Requirements for Manufacturers of Fuels and Fuel Additives

EPA Issues ICR Concerning Health Effects Research Requirements for Manufacturers of Fuels and Fuel Additives

EPA also has established alternative Tier 2 requirements for the manganese additive MMT manufactured by the Afton Chemical Corporation (formerly the Ethyl Corporation). ...

ByBergeson & Campbell, P.C.


EPA Issues ICR Concerning Health Effects Research Requirements for Manufacturers of Fuels and Fuel Additives

EPA Issues ICR Concerning Health Effects Research Requirements for Manufacturers of Fuels and Fuel Additives

EPA also has established alternative Tier 2 requirements for the manganese additive MMT manufactured by the Afton Chemical Corporation (formerly the Ethyl Corporation). ...

ByActa Group


ASTM F2180 - 02(2011)e1 Standard Specification for Metallic Implantable Strands and Cables

ASTM F2180 - 02(2011)e1 Standard Specification for Metallic Implantable Strands and Cables

Referenced Documents (purchase separately) American Society for Quality (ASQ) Standard ASQC1 Specification of General Requirements for a Quality Program Department of Defense Specifications MIL-DTL-83420/2B Wire Rope, Flexible, Type 1, Composition B ASTM Standards E8 Test Methods for Tension Testing of Metallic Materials F86 Practice for Surface Preparation and Marking of Metallic ...

ByASTM International


ASTM A453 / A453M - 11 standard specification for high-temperature bolting, with expansion coefficients comparable to austenitic stainless steels

ASTM A453 / A453M - 11 standard specification for high-temperature bolting, with expansion coefficients comparable to austenitic stainless steels

Materials shall adhere to specified contents of carbon, manganese, phosphorus, sulfur, silicon, nickel, chromium, molybdenum, tungsten, titanium, columbium, aluminum, vanadium, boron, and copper. ...

ByASTM International


Manganese inhaled from the shower - A public health threat? maybe

Manganese inhaled from the shower - A public health threat? maybe

Once inside these small nerves, manganese can travel throughout the brain." Elsner and Spangler extrapolated data from rodents to estimate human exposure to manganese during showering. They found that after 10 years of showering in manganese contaminated water, children would be exposed to doses of manganese three times higher ...

ByFiltronics, Incorporated

  • Previous
  • Next
Need help finding the right suppliers?Try XPRT Sourcing. Let the XPRTs do the work for you
Back to top
About Medical XPRT

Medical XPRT is a global marketplace with solutions and suppliers for the medical sector, with product catalogs, articles, industry events, publications & more.

Channels

Solutions

  • Medical XPRT Industry Products
  • Medical XPRT Industry Software
  • Medical XPRT Industry Training
  • Medical XPRT Industry Services
  • Medical XPRT Industry Applications

Latest

  • Medical XPRT Industry News
  • Medical XPRT Industry Events

Publications

  • Medical XPRT Industry Articles
  • Medical XPRT Industry Books
  • Medical XPRT Industry Magazines
  • Medical XPRT Industry Downloads
  • Medical XPRT Industry Videos

Companies

  • Medical XPRT Industry Companies

  • FAQs
  • Company sitemap
  • Category sitemap
Medical XPRT is part of XPRT Media All Rights Reserved.
Terms
Privacy
  • Medical XPRT RSS List
Our sites:
Environmental XPRT
Agriculture XPRT
Energy XPRT
XPRT